PT  - JOURNAL ARTICLE
AU  - Antony Raharja
AU  - Satveer K Mahil
AU  - Jonathan N Barker
TI  - Psoriasis: a brief overview
AID  - 10.7861/clinmed.2021-0257
DP  - 2021 May 01
TA  - Clinical Medicine
PG  - 170--173
VI  - 21
IP  - 3
4099  - http://www.rcpjournals.org/content/21/3/170.short
4100  - http://www.rcpjournals.org/content/21/3/170.full
SO  - Clin Med2021 May 01; 21
AB  - Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular or erythrodermic. An estimated 60 million people have psoriasis worldwide, with 1.52% of the general population affected in the UK. An immune-mediated inflammatory disease, psoriasis has a major genetic component. Its association with psoriatic arthritis and increased rates of cardiometabolic, hepatic and psychological comorbidity requires a holistic and multidisciplinary care approach. Psoriasis treatments include topical agents (vitamin D analogues and corticosteroids), phototherapy (narrowband ultraviolet B radiation (NB-UVB) and psoralen and ultraviolet A radiation (PUVA)), standard systemic (methotrexate, ciclosporin and acitretin), biologic (tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors) or small molecule inhibitor (dimethyl fumarate and apremilast) therapies. Advances in the understanding of its pathophysiology have led to development of highly effective and targeted treatments.